NCT02988843终止2 期
Phase II Study of Brentuximab Vedotin and Bevacizumab in Men With Refractory CD-30 Positive Germ Cell Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Disease Response Rate as Defined by the RECIST 1.1 Criteria, Integrated With Tumor Marker Response.
研究概览
简要总结
This is a multi-center phase II study of brentuximab vedotin in combination with bevacizumab for the treatment of refractory CD-30+ germ cell tumors (GCT) after disease progression on imaging and/or tumor marker progression documented by serially rising alpha-fetoprotein (AFP) or beta human chorionic gonadotropin (bHCG) measured on at least 2 consecutive visits and determined by treating physician to be clinically significant. Patients unable to receive 2nd line of platinum-based chemotherapy due to toxicity or refusal would also be eligible.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male, ≥ 18 years of age
- •Diagnosis of CD-30 positive germ cell tumor. CD30 expression will be tested by immunohistochemistry (IHC) in archival or fresh tumor tissue as is routinely done for diagnosis.
- •Disease progression on imaging or tumor marker progression (clinical significance of tumor marker progression to be decided per the discretion of treating physician) after at least 2 lines of platinum-based chemotherapies unless patient is ineligible for further platinum based chemotherapy or refuses 2nd line platinum based chemotherapy due to toxicity. For primary mediastinal germ cell tumors, failure of first-line chemotherapy will be accepted. Prior high dose chemotherapy with hematopoietic stem cell rescue is allowed. Prior treatment with bevacizumab is allowed.
- •At least 3 weeks should have elapsed since the last treatment (e.g. chemotherapy, targeted small molecule therapy, immunotherapy or radiation) and must have recovered to grade 1 or better from the acute effects of prior therapy.
- •Presence of measurable disease according to RECIST 1.1
- •ECOG performance status 0 or 1
- •Adequate marrow and organ function within 28 days prior to study registration as defined below:
- •Leukocytes > 3,000/µL
- •ANC > 1500/µL
- •Hemoglobin ≥ 9 g/dL, Note: Blood transfusion will be allowed for patients with hemoglobin < 9 g/dl and G-CSF is allowed for neutropenic patients at time of enrollment.
- •Platelets > 100,000/mm3
- •Creatinine: ≤3mg/dl OR if serum creatinine > 3 mg/dl, estimated GFR >30 mL/min/1.73m2
- •INR: <1.5 x institutional upper limit of normal OR < 3 if on warfarin or other anticoagulants. There should be no evidence of active bleeding while on anticoagulants.
- •Total bilirubin: ≤ 2 x institutional upper limit of normal (ULN)
- •SGOT (AST) or SGPT (ALT): < 3 x institutional upper limit of normal (< 5 x ULN if liver metastases present)
- •Proteinuria: If patient has proteinuria, it should be <2+ (< 100 mg/dl or per institutional guidelines). If proteinuria is 2+ or greater (≥ 100 mg/dl per institutional guidelines), patients should undergo a 24- hour urine collection and 24 hour urinary protein should be less than < 2 grams.
- •Sexually active men with partners of women of childbearing potential must agree to practice effective methods of contraception during the study and for 6 months after the last treatment
- •Provide voluntary written consent and HIPAA authorization for release of personal health information, approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC)
排除标准
- •Prior treatment with Brentuximab Vedotin.
- •Known active brain metastases and or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided brain metastases are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to study registration. This exception does not include carcinomatous meningitis, which is excluded regardless of clinical stability.
- •History of blood clots, pulmonary embolism, or deep vein thrombosis in previous 6 months unless controlled by anticoagulant treatment
- •Known history of HIV
- •Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected)
- •Received a live vaccine within 1 week prior to the first dose of study treatment
- •Has active autoimmune disease that required systemic treatment with use of disease modifying agents, corticosteroids or immunosuppressive drugs
- •Any clinically significant active infection that requires systemic treatment at the time of enrollment.
- •Known allergy to bevacizumab or brentuximab vedotin or any of its excipients
- •Patients who have congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation, clinically significant bradycardia, advanced heart block or a history of acute myocardial infarction (MI) within 6 months of study registration
- •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess in previous 6 months
- •Prior major surgery within the previous 28 days of study registration and/or presence of any non-healing wound, fracture, or ulcer.
- •Use of an investigational agent within the previous 28 days of study registration.
- •Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥150 mmHg and/or diastolic blood pressure (DBP) of ≥ 90mmHg]. Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study registration
- •Arterial thromboembolic events, including transient ischemic attack (TIA), cerebrovascular accident (CVA), unstable angina, or MI within 6 months of study registration
- •History of posterior reversible encephalopathy syndrome
- •Other malignancies unless the patient is considered to be disease-free and has completed therapy for the malignancy > than 6 months prior to study entry
- •Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures
- •Concurrent use of rifampin or ketoconazole
研究组 & 干预措施
Brentuximab Vedotin & Bevacizumab
Experimental
- Bevacizumab will be administered at a dose of 15 mg/kg IV every 21 days; over 90 minutes during 1st infusion, over 60 minutes as 2nd infusion and over 30 minutes for subsequent infusions if prior infusions well tolerated.
- Brentuximab vedotin will be administered first at 1.8 mg/kg (maximum dose of 180 mg) IV over 30 minutes every 21 days.
干预措施: Brentuximab Vedotin (Drug)
Brentuximab Vedotin & Bevacizumab
Experimental
- Bevacizumab will be administered at a dose of 15 mg/kg IV every 21 days; over 90 minutes during 1st infusion, over 60 minutes as 2nd infusion and over 30 minutes for subsequent infusions if prior infusions well tolerated.
- Brentuximab vedotin will be administered first at 1.8 mg/kg (maximum dose of 180 mg) IV over 30 minutes every 21 days.
干预措施: Bevacizumab (Drug)
结局指标
主要结局
Disease Response Rate as Defined by the RECIST 1.1 Criteria, Integrated With Tumor Marker Response.
时间窗: 1 year
Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria. In addition to CT scan to assess for disease evaluation, whole body bone scans will be done for patients with known or suspected bone metastases to assess for bone lesions.
次要结局
- Number of Participants Experiencing Progression Free Survival(2 years)
- Number of Participants Who Were Alive at 2 Years - Overall Survival(2 years)
- Number of Participants Experiencing Adverse Events (AE) and Severe Adverse Events (SAE)(2 Years)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaDiffuse Large B Cell LymphomaMediastinal Large B-cell LymphomaGrey Zone LymphomaHigh Grade B Cell LymphomaMarginal Zone LymphomaSmall Lymphocytic LymphomaFollicular LymphomaNCT02623920University of Arizona
招募中
2 期
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint InhibitorsRecurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin LymphomaNCT05039073Emory University46
撤回
2 期
Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell LymphomaRecurrent Angioimmunoblastic T-Cell LymphomaRecurrent Enteropathy-Associated T-Cell LymphomaRecurrent Follicular T-Cell LymphomaRecurrent Hepatosplenic T-Cell LymphomaRecurrent Nodal Peripheral T-Cell Lymphoma With TFH PhenotypeRecurrent Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Subcutaneous Panniculitis-Like T-Cell LymphomaRefractory Angioimmunoblastic T-Cell LymphomaRefractory Enteropathy-Associated T-Cell LymphomaRefractory Follicular T-Cell LymphomaRefractory Hepatosplenic T-Cell LymphomaRefractory Nodal Peripheral T-Cell Lymphoma With TFH PhenotypeRefractory Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRefractory Subcutaneous Panniculitis-Like T-Cell LymphomaNCT04795869Northwestern University
招募中
2 期
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular LymphomaRecurrent Follicular LymphomaRefractory Follicular LymphomaNCT04587687University of California, Davis23
招募中
2 期
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin LymphomaRelapsed Classic Hodgkin LymphomaNCT04561206City of Hope Medical Center31